Product Highlight - EVRENZO

New Launch of Evrenzo^®, time to rethink CKD Anemia Treatment for dialysis dependent (DD) and non-dialysis dependent (NDD) CKD Patients

• Evrenzo^® targets the HIF pathway which promotes endogenous erythropoietin (EPO) production and improves iron absorption and mobilization, resulting in a coordinated erythropoietic response.¹

• Evrenzo^® is an oral therapy, offering an alternative to the traditional ESA injection.²

• Evrenzo^® achieves a high Hb target (Hb ≥110 g/L) attainment rate with clinical data showing up to 84% of NDD patients reaching their Hb targets after 26 weeks of treatment, and up to 88% of DD patients achieving their Hb targets after 24 weeks of treatment.^{6, 7}

• Evrenzo^® can reduce the need for IV iron.^{3, 4}

• Evrenzo^® has a comparable safety profile vs. current Standard of Care.^{5, 8}

References:
1. Li Y, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicentre, cross-sectional study. Medicine. 2016 Jun 1;95(24):e3872
2. Evrenzo^® Hong Kong Prescribing Information (Sep 2024)
3. Barratt J, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021 Sep 1;36(9):1616-28.
4. Charytan C, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021 Jul 1;6(7):1829-39.
5. Provenzano R, et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: Pooled results of three randomized clinical trials. Clin J Am Soc Nephrol. 2021 Aug 1;16(8):1190-200.
6. Chen N, et al. N Engl J Med 2019,381(11):1001-1010
7. Provenzano R, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021 Aug 27;36(9):1717-1730
8. Barratt J, et al. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Adv Ther.2021;38(10):5345-5360.

HK-11484 04/03/2025

Please scan the QR code for the abbreviated Prescribing information